FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281738507> ?p ?o ?g. }

• W4281738507 endingPage "3073" @default.
• W4281738507 startingPage "3073" @default.
• W4281738507 abstract "3073 Background: Comprehensive genomic profiling (CGP) is increasingly used to guide therapy selection in advanced cancer patients who have exhausted standard therapy options. Here we assess the utility of Therapy Oriented Precision Oncology Guidelines for Recommending Anticancer Pharmaceuticals (TOPOGRAPH) to guide matching of drug treatments based on CGP in this setting. Methods: This study was conducted in an Australia-wide precision oncology program, the Molecular Screening and Therapeutics Study (MoST, ANZCTR registration ACTRN12616000908437). All patients with advanced cancer after exhausting standard treatments underwent CGP in 2016-2021 were stratified into cohort A (no further therapy received) and B (received ≥1 therapy after CGP). The primary outcome was overall survival (OS) estimated by the Kaplan-Meier method, using the log rank test to assess between-group differences. TOPOGRAPH matched the treatment history to the CGP results, stratified into clinically active (Tiers 1-3, T1-3), investigational (T3B/4), inactive (R2) or unmatched groups. Results: Over a median follow-up of 21.7 months (mo) for 2852 patients (75% with rare cancers, n = 2150), the median OS (mOS) from the date of CGP result was 7.0 mo (95% CI 6.4-7.6) for cohort A (n = 1562) and 15.8 mo (95% CI 14.5-16.9) for cohort B (n = 1290). In both cohorts, patients with CGP results matching any TOPOGRAPH tier (T1-4) had shorter OS compared to patients without a matching tier (A: 6.4 v 20.5 mo, hazard ratio for death [HR] 2.15, p<0.001; B: 14.7 v 23.6 mo, HR 1.43, p<0.001). Patients in cohort B receiving matched therapy (n=342, 27%) had a longer mOS than 948 patients who received only unmatched therapy (16.9 v 10.4 mo, HR 0.70, p<0.001). For CGP results matched to T1-3, 122 patients who received a T1-3 therapy had a significantly longer mOS than those who received unmatched therapy (22.1 v 9.8 mo, HR 0.51, p<0.001). For CGP results matched only to T3B/4, a trend toward longer mOS was observed in patients receiving matched therapy in T3B/4 (n = 138, 14.5 v unmatched 10.0 mo, HR 0.81, P = 0.07). In tier-matched analysis, the mOS were not significantly different between patients who received genomics matched v unmatched therapy in T3B (matching outside cognate histotypes, n = 48 v 508, 11.9 v 9.7 mo, HR 0.84, p = 0.36) and T4 (n = 32 v 134; therapy with preclinical/early clinical evidence, 17.1 v 12.2 mo, HR 0.69, p = 0.17). Conclusions: TOPOGRAPH is prognostic and likely predictive of treatment effect based on CGP, supporting its utility in guiding molecular therapy selection in patients who have exhausted standard treatment options. [Table: see text]" @default.
• W4281738507 created "2022-06-13" @default.
• W4281738507 creator A5012688551 @default.
• W4281738507 creator A5013670225 @default.
• W4281738507 creator A5016213925 @default.
• W4281738507 creator A5016371744 @default.
• W4281738507 creator A5031105664 @default.
• W4281738507 creator A5032181613 @default.
• W4281738507 creator A5032806596 @default.
• W4281738507 creator A5037578765 @default.
• W4281738507 creator A5049432704 @default.
• W4281738507 creator A5051679566 @default.
• W4281738507 creator A5052524387 @default.
• W4281738507 creator A5053026663 @default.
• W4281738507 creator A5056579841 @default.
• W4281738507 creator A5057483557 @default.
• W4281738507 creator A5069452886 @default.
• W4281738507 creator A5071066396 @default.
• W4281738507 creator A5077916068 @default.
• W4281738507 creator A5078038970 @default.
• W4281738507 creator A5080428614 @default.
• W4281738507 creator A5082768519 @default.
• W4281738507 date "2022-06-01" @default.
• W4281738507 modified "2023-09-27" @default.
• W4281738507 title "Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base." @default.
• W4281738507 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3073" @default.
• W4281738507 hasPublicationYear "2022" @default.
• W4281738507 type Work @default.
• W4281738507 citedByCount "0" @default.
• W4281738507 crossrefType "journal-article" @default.
• W4281738507 hasAuthorship W4281738507A5012688551 @default.
• W4281738507 hasAuthorship W4281738507A5013670225 @default.
• W4281738507 hasAuthorship W4281738507A5016213925 @default.
• W4281738507 hasAuthorship W4281738507A5016371744 @default.
• W4281738507 hasAuthorship W4281738507A5031105664 @default.
• W4281738507 hasAuthorship W4281738507A5032181613 @default.
• W4281738507 hasAuthorship W4281738507A5032806596 @default.
• W4281738507 hasAuthorship W4281738507A5037578765 @default.
• W4281738507 hasAuthorship W4281738507A5049432704 @default.
• W4281738507 hasAuthorship W4281738507A5051679566 @default.
• W4281738507 hasAuthorship W4281738507A5052524387 @default.
• W4281738507 hasAuthorship W4281738507A5053026663 @default.
• W4281738507 hasAuthorship W4281738507A5056579841 @default.
• W4281738507 hasAuthorship W4281738507A5057483557 @default.
• W4281738507 hasAuthorship W4281738507A5069452886 @default.
• W4281738507 hasAuthorship W4281738507A5071066396 @default.
• W4281738507 hasAuthorship W4281738507A5077916068 @default.
• W4281738507 hasAuthorship W4281738507A5078038970 @default.
• W4281738507 hasAuthorship W4281738507A5080428614 @default.
• W4281738507 hasAuthorship W4281738507A5082768519 @default.
• W4281738507 hasConcept C121332964 @default.
• W4281738507 hasConcept C121608353 @default.
• W4281738507 hasConcept C126322002 @default.
• W4281738507 hasConcept C142424586 @default.
• W4281738507 hasConcept C143998085 @default.
• W4281738507 hasConcept C167135981 @default.
• W4281738507 hasConcept C207103383 @default.
• W4281738507 hasConcept C2781230642 @default.
• W4281738507 hasConcept C44249647 @default.
• W4281738507 hasConcept C71924100 @default.
• W4281738507 hasConcept C72563966 @default.
• W4281738507 hasConcept C87355193 @default.
• W4281738507 hasConceptScore W4281738507C121332964 @default.
• W4281738507 hasConceptScore W4281738507C121608353 @default.
• W4281738507 hasConceptScore W4281738507C126322002 @default.
• W4281738507 hasConceptScore W4281738507C142424586 @default.
• W4281738507 hasConceptScore W4281738507C143998085 @default.
• W4281738507 hasConceptScore W4281738507C167135981 @default.
• W4281738507 hasConceptScore W4281738507C207103383 @default.
• W4281738507 hasConceptScore W4281738507C2781230642 @default.
• W4281738507 hasConceptScore W4281738507C44249647 @default.
• W4281738507 hasConceptScore W4281738507C71924100 @default.
• W4281738507 hasConceptScore W4281738507C72563966 @default.
• W4281738507 hasConceptScore W4281738507C87355193 @default.
• W4281738507 hasIssue "16_suppl" @default.
• W4281738507 hasLocation W42817385071 @default.
• W4281738507 hasOpenAccess W4281738507 @default.
• W4281738507 hasPrimaryLocation W42817385071 @default.
• W4281738507 hasRelatedWork W2084898420 @default.
• W4281738507 hasRelatedWork W2326652628 @default.
• W4281738507 hasRelatedWork W2476973162 @default.
• W4281738507 hasRelatedWork W2515906920 @default.
• W4281738507 hasRelatedWork W2538611412 @default.
• W4281738507 hasRelatedWork W2586635754 @default.
• W4281738507 hasRelatedWork W2762861864 @default.
• W4281738507 hasRelatedWork W2906013683 @default.
• W4281738507 hasRelatedWork W2989830802 @default.
• W4281738507 hasRelatedWork W4366463132 @default.
• W4281738507 hasVolume "40" @default.
• W4281738507 isParatext "false" @default.
• W4281738507 isRetracted "false" @default.
• W4281738507 workType "article" @default.